Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KORU Medical Systems (KRMD) Receivables (2020 - 2025)

KORU Medical Systems has reported Receivables over the past 10 years, most recently at $4.0 million for Q4 2025.

  • Quarterly results put Receivables at $4.0 million for Q4 2025, down 32.98% from a year ago — trailing twelve months through Dec 2025 was $4.0 million (down 32.98% YoY), and the annual figure for FY2025 was $4.0 million, down 32.98%.
  • Receivables for Q4 2025 was $4.0 million at KORU Medical Systems, down from $5.5 million in the prior quarter.
  • Over the last five years, Receivables for KRMD hit a ceiling of $6.3 million in Q1 2025 and a floor of $31489.0 in Q4 2023.
  • Median Receivables over the past 5 years was $4.5 million (2021), compared with a mean of $4.1 million.
  • Biggest five-year swings in Receivables: crashed 99.01% in 2023 and later skyrocketed 18947.74% in 2024.
  • KORU Medical Systems' Receivables stood at $4.3 million in 2021, then decreased by 26.41% to $3.2 million in 2022, then crashed by 99.01% to $31489.0 in 2023, then skyrocketed by 18947.74% to $6.0 million in 2024, then tumbled by 32.98% to $4.0 million in 2025.
  • The last three reported values for Receivables were $4.0 million (Q4 2025), $5.5 million (Q3 2025), and $5.1 million (Q2 2025) per Business Quant data.